Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued [GID-TA10970]
Discontinued [GID-TA10970]
We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.
We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.
We are listening to your views on this Medical technologies guidance. Comments close 16 June 2022.
We are listening to your views on this Technology appraisal guidance. Comments close 13 June 2022.
Discontinued [GID-TAG390]
Discontinued [GID-TAG402]
Discontinued [GID-TAG396]
Discontinued [GID-TAG372]
Discontinued [GID-MT516]
Discontinued [GID-TAG239]
Discontinued [GID-PHG59]
Discontinued [GID-MT267]
Discontinued [GID-PHG0]
Discontinued [GID-MT517]
Discontinued [GID-MT163]
Discontinued [GID-TAG385]
Discontinued [GID-TAG400]
Discontinued [GID-TAG416]
Discontinued [GID-TAG408]
Discontinued [GID-MT117]
Discontinued [GID-TA10087]
Discontinued [GID-TAG377]
Discontinued [GID-TAG241]
Discontinued [GID-MT130]
Discontinued [GID-MT544]
Discontinued [GID-TAG378]
Discontinued [GID-TA10236]
Discontinued [GID-TAG375]
Discontinued [GID-TAG398]
Discontinued [GID-TAG371]
Discontinued [GID-TAG370]
Discontinued [GID-TAG411]
Discontinued [GID-TA10462]
Discontinued [GID-MT81]
Discontinued [GID-TAG404]
Discontinued [GID-TAG368]
Discontinued [GID-PHG58]
Discontinued [GID-MT536]
Discontinued [GID-TAG399]
Discontinued [GID-NG10053]
Discontinued [GID-TAG511]
Discontinued [GID-TAG382]
Discontinued [GID-TAG393]
Discontinued [GID-TAG397]
Discontinued [GID-TAG374]
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
Discontinued [GID-TA10502]
Discontinued [GID-TAG414]
Discontinued [GID-TA10088]